Summary The clinical efficacy of solid tumor CAR-T therapies hinges on overcoming metabolic barriers within the tumor microenvironment. This article explores how tracking CD8+ T cell metabolic reprogramming, glucose competitive kinetics, and cytokine secretion feedback can guide the precise engineering of persistence-enhanced cell therapies.   While Chimeric Antigen Receptor (CAR) T-cell...

The cell therapy industry is moving toward more precise, scalable, and controllable immunotherapies. As researchers address challenges in CIK cell potency, consistency, and manufacturing complexity, Creative Biolabs provides advanced CIK development solutions supporting the future of cancer immunotherapy innovation.   The global cell therapy industry is entering a new stage of innovation,...

CRISPR-based screening is a cutting-edge, high-throughput approach that uses CRISPR-Cas systems to systematically explore gene function by modulating gene expression at the genomic level. This approach is increasingly recognized as a powerful tool for functional genomics, allowing scientists to uncover genes essential for cell survival, drug resistance, immune modulation, or disease...

We offer a specialized genome-wide CRISPR screening service, leveraging the precision of CRISPR knockout (CRISPRko) technology to systematically explore gene functions across the genome. Using sgRNA libraries to induce targeted gene disruptions, CRISPRko screens help identify genes critical for phenotypes like drug resistance, cell viability, and proliferation. This high-throughput approach is...

We provide CM13 helper phage production services for research workflows that rely on helper phage support in phagemid-based display systems. Our service includes CM13 helper phage production, amplification, titering, purification, and analytical evaluation, with project discussions aligned to the intended use of the material in phage display-related studies.

M13KO7 is commonly used in phagemid systems to supply the gene products required for phage particle formation while favoring packaging of phagemid DNA carrying a wild-type M13 or f1 origin. In research settings, it is widely associated with ssDNA preparation and phage display-related applications. Building on this role, we offer M13KO7 helper phage production together with related support that...

Anti-Influenza HA Neutralizing Antibody This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Group 2 influenza virus HA hemagglutinin. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an...

Anti-IAV H1 Subtype HA Neutralizing Antibody This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Influenza A virus H1 subtype hemagglutinin. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis....

Within Anti-Glycan Antibody Research Services, we offers a glycan and glycopeptide immunogen design service built for projects in which antigen presentation determines whether an antibody campaign starts with a meaningful epitope or with an over-simplified conjugate. When difficult antigens are weakly immunogenic, highly glycoform dependent, or strongly influenced by carrier protein and linker...

Disease-associated remodeling of glycosaminoglycans (GAGs), particularly at the level of sulfation motifs and domain organization, has been extensively documented in oncology and other pathologies. These observations support the research value of developing precision anti-GAG antibodies for mapping, selectivity analysis, and target evaluation.